Editorial: P2X7 as Common Therapeutic Target in Brain Diseases

Front Mol Neurosci. 2021 Apr 27:14:656011. doi: 10.3389/fnmol.2021.656011. eCollection 2021.

Tobias Engel^{1

2}, Annette Nicke³, Jan M Deussing⁴, Beata Sperlagh⁵, Miguel Diaz-Hernandez^{6

7}

¹ Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland.
² FutureNeuro, Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, Dublin, Ireland.
³ Faculty of Medicine, Walther Straub Institute of Pharmacology and Toxicology, Ludwig-Maximilians-Universität München, Munich, Germany.
⁴ Molecular Neurogenetics, Max Planck Institute of Psychiatry, Munich, Germany.
⁵ Laboratory of Molecular Pharmacology, Institute of Experimental Medicine, Budapest, Hungary.
⁶ Department of Biochemistry and Molecular Biology, Veterinary School, Complutense University of Madrid, Madrid, Spain.
⁷ Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain.

No abstract available

Keywords: ATP; P2X7 receptor; brain diseases; purinergic signaling; shared pathological pathways.

Publication types